Histone Demethylases

45 Items

per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Product Citation
  1. KDM5A inhibitor

    YUKA1 is a potent and cell permeable Lysine demethylase 5A (KDM5A) inhibitor, with an IC50 of 2.66 μM.
  2. KDM4A inhibitor

    Toxoflavin (Xanthothricin) is an antagonist of transcription factor 4 (TCF4)/β-catenin complex, also acts as an inhibitor of KDM4A, with antitumor activity.
  3. Demethylase Inhibitor

    GSK J4 is a cell permeable prodrug rapidly hydrolyzed by macrophage esterases to GSK-J1, a potent selective jumonji H3K27 demethylase inhibitor; attenuates lipopolysaccharide (LPS)-induced proinflammatory cytokine production in primary human macrophages (IC50 = 9 uM for the inhibition of TNF?? release).
  4. LSD1 inhibitor

    CBB1003 is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.
  5. plant growth regulator

    Daminozide(DMASA; DIMG; B 995), a plant growth regulator, selectively inhibits the KDM2/7 JmjC subfamily.
  6. Histone demethylase inhibitor

    GSK J1 is a potent and selective inhibitor of the H3K27 histone demethylases JMJD3 and UTX
  7. LSD1 Inhibitor

    LSD1-C76 is a potent and selective Lysine Specific Demethylase-1 (LSD1) inhibitor.
  8. KDM4B inhibitor

    NCGC00244536 is a potent KDM4B inhibitor with an IC50 of 10 nM.
  9. LSD1 inhibitor

    OG-L002 is a potent and specific LSD1 inhibitor with IC50 of 20 nM, exhibiting 36- and 69-fold selectivity over MAO-B and MAO-A, respectively.
  10. LSD1/BHC110 & MAO inhibitor

    Tranylcypromine hydrochloride is a non-selective MAO-A/B inhibitor.
  11. Histone Demethylase inhibitor

    JIB-04 is a pan-selective Jumonji histone demethylase inhibitor with IC50 of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively.
  12. 2OG oxygenases Inhibitor

    IOX1 is a potent and broad-spectrum inhibitor of 2OG oxygenases, including the JmjC demethylases.
  13. JARID1 inhibitor

    PBIT is a reversible, cell-permeable inhibitor of JARID1 family demethylases (IC50s = 6, 3, 4.9, and 28 uM for JARID1A, JARID1B, JARID1C, and JARID1D, respectively).
  14. LSD1 inhibitor

    SP2509 is a novel histone demethylase LSD1 (KDM1A) antagonist with IC50 of 13 nM; no inhibition on MAO-A and MAO-B.
  15. LSD1 inhibitor

    GSK2879552 is an orally available, irreversible, inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity.
  16. JMJD2 inhibitor?€?

    ML-324 is a potent JMJD2 demethylase inhibitor with demonstrated antiviral activity.
  17. LSD1 Inhibitor

    ORY-1001 is an orally active and selective lysine-specific demethylase LSD1/KDM1A inhibitor with IC50 of <20 nM, with high selectivity against related FAD dependent aminoxidases. Phase 1.
  18. KDM5 demethylases inhibitor

    CPI 4203 is a selective inhibitor of KDM5 demethylases, structurally related to CPI 455 but ~25-fold less potent (IC50 value 250 nM for inhibition of full length KDM5A).
  19. KDM5 inhibitor

    CPI 455 possesses the target specificity required for an in vitro tool compound for exploring KDM5-dependent disease biology, including drug tolerance.
  20. KDM5 inhibitor.

    AS8351 is a histone demethylase inhibitor.
  21. KDM inhibitor

    2,4-Pyridinedicarboxylic Acid (2,4-PDCA) is an inhibitor of histone lysine-specific demethylases that targets on JMJD2A (KDM4A), KDM4C, KDM4E (IC50, 1.4 μM), KDM5B (IC50, 3 μM), KDM6A and other 2-oxogynases.
  22. KDM2/7 inhibitor

    TC-E 5002, selective histone demethylase KDM2/7 subfamily inhibitor (IC50 values are 0.2, 1.2, 6.8, 55, 83, >100 and >120 uM for KDM7A, KDM7B, KDM2A, KDM5A, KDM4C, KDM6A and KDM4A respectively). Inhibits growth of HeLa and KYSE-150 cancer cells in vitro.
  23. LSD1 inhibitor

    CBB1007 is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 μM for hLSD1).
  24. Procaine hydrochloride is a local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block.
  25. Eicosapentaenoic Acid (EPA; Timnodonic acid) is an omega-3 fatty acid.
  26. LSD1 inhibitor

    T-3775440 (hydrochloride) is an irreversible lysine-specific histone demethylase (LSD1) inhibitor with an IC50 value of 2.1 nM.
  27. KDM5B (JARID1B or PLU1) inhibitor

    GSK467 is a potent and selective inhibitor of KDM5 (also known as JARID1) with a Ki of 10 nM, shows 180-fold selectivity for KDM4C and no measurable inhibitory effects toward KDM6 or other Jumonji family members. GSK467 exploits unique binding modes.
  28. KDM4/KDM5 dual inhibitor

    KDM4-IN-2 (Compound 19a) is a potent and selective KDM4/KDM5 dual inhibitor with Kis of 4 and 7?nM for KDM4A and KDM5B, respectively.
  29. KDM4C inhibitor

    QC6352 is a potent KDM4C inhibitor with an IC50 of 35 nM.
  30. KDM4 inhibitor

    NCGC00247743 is a histone lysine demethylase KDM4 inhibitor.
  31. KDM4D inhibitor

    KDM4D-IN-1 is a new histone lysine demethylase 4D (KDM4D) inhibitor with an IC50 value of 0.41±0.03 μM.
  32. LSD1 inhibitor

    Corin is a dual inhibitor of histone lysine specific demethylase (LSD1) and histone deacetylase (HDAC), with a Ki(inact) of 110 nM for LSD1 and an IC50 of 147 nM for HDAC1.
  33. LSD1 inhibitor

    S 2101 is a lysine-specific demethylase 1 (LSD1) inhibitor with an IC50 of 0.99 μM, Ki of 0.61 μM and Kinact/Ki of 4560 M/s.
  34. KDM2A/7A inhibitor

    KDM2A/7A-IN-1 is a first-in-class, selective and cell-permeable inhibitor of histone lysine demethylases KDM2A/7A, with an IC50 of 0.16?μM for KDM2A, exhibits 75 fold selevtivity over other JmjC lysine demethylases, and is inactive on methyl transferases, and histone acetyl transferases.
  35. LSD1 inhibitor

    Seclidemstat (SP-2577) is a potent and orally bioavailable LSD1 inhibitor, with a mean IC50 of 127 nM.
  36. LSD1/MAO-B inhibitor

    Vafidemstat (ORY-2001) is a dual lysine-specific histone demethylase (LSD1)/MAO-B inhibitor.
  37. KDM5 inhibitor

    KDM5A-IN-1 is a potent, orally bioavailable pan-histone lysine demethylases 5 (KDM5) inhibitor with IC50s of 45 nM, 56 nM and 55 nM for KDM5A, KDM5B and KDM5C, respectively, and with an EC50 value of 960 nM for PC9 H3K4Me3.
  38. LSD1 inhibitor

    LSD1-IN-6 (Compound 4m) is a potent and reversible inhibitor of lysine-specific demethylase 1 (LSD1), with an IC50 of 123 nM. LSD1-IN-6 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1.
  39. LSD1 inhibitor

    LSD1-IN-5 (Compound 4e) is a potent and reversible inhibitor of lysine-specific demethylase 1 (LSD1), with an IC50 of 121 nM. LSD1-IN-5 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1.
  40. KDM5 inhibitor

    KDM5-IN-1 is a potent, selective and orally bioavailable KDM5 inhibitor with an IC50 of 15.1 nM.
  41. KDM1A/LSD1 inhibitor

    ORY-1001 trans is a selective irreversible lysine (K)-specific demethylase 1A (KDM1A/LSD1) inhibitor.
  42. LSD1 inhibitor

    GSK-LSD1 dihydrochloride is a potent, selective and irreversible lysine specific demethylase 1 (LSD1) inhibitor with an IC50 of 16 nM.
  43. LSD1 inhibitor

    T-448 is a specific and irreversible inhibitor of lysine-specific demethylase 1 (LSD1, an H3K4 demethylase), with an IC50 of 22 nM.
  44. Jumonji histone demethylase inihibitor

    Z-JIB-04 (NSC 693627, JIB-04 Z-isomer) is an isomer of JIB-04. JIB-04 is a pan-selective Jumonji histone demethylase inihibitor with IC50 of 230 nM, 340 nM, 855 nM, 445 nM, 435 nM, 1100 nM and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively.
  45. epigenetic modifier

    L-2-Hydroxyglutaric acid disodium ((S)-2-Hydroxyglutaric acid disodium, L-2-Hydroxyglutarate disodium, LGA, L-2HG) is an epigenetic modifier and a putative oncometabolite in kidney cancer that inhibits histone demethylases and hence promotes histone methylation.

45 Items

per page
Set Descending Direction